You've tried the medications. They haven't worked. There is a next step.
What treatment-resistant depression actually means.
-
Affects an estimated one-third of people with major depressive disorder
-
Defined clinically as inadequate response to two or more antidepressants
-
Can persist for years despite consistent treatment attempts
-
Often accompanied by significant impact on work, relationships, and daily functioning
Signs you may have treatment-resistant depression.
-
You have been diagnosed with major depressive disorder.
-
You have tried two or more antidepressants without adequate improvement.
-
Your depression has persisted for months or years despite treatment.
-
You feel like you have exhausted the standard options.
-
Your psychiatrist or doctor has suggested you explore other approaches.
-
You are still experiencing significant symptoms even while taking medication.
How PMC Psychedelic treats treatment-resistant depression.
Spravato® (Esketamine)
- FDA-approved specifically for treatment-resistant depression
- Nasal spray, administered in-office under supervision
- Most PPO insurance plans cover it — we verify in advance
- Many patients notice improvement within hours of early sessions
Ketamine IV Infusion
- Intravenous ketamine with strong clinical evidence for TRD
- Precise, controlled dosing administered by our medical team
- No insurance required — paid out of pocket
- Often used when Spravato is not covered or clinically preferred
What our patients typically experience.
Common questions.
Clinically, TRD is defined as inadequate response to two or more antidepressants at adequate doses. If you have tried multiple medications without meaningful improvement, you may qualify. A consultation with Dr. Rueda is the only way to confirm this for your specific situation.
Spravato (esketamine) is FDA-approved specifically for TRD and is covered by most PPO insurance plans. We verify your coverage before your first appointment. Ketamine IV infusion is not covered by insurance and is paid out of pocket.
Many patients with TRD notice meaningful improvement within 24 to 48 hours of one of their first sessions. Others experience more gradual improvement over the first two to three weeks. Results vary significantly by individual.
In most cases, yes. Spravato is approved for use alongside an oral antidepressant, and Ketamine IV is also compatible with most medications. Dr. Rueda will review your full medication history during your evaluation.
Prior ketamine treatment does not disqualify you. Dr. Rueda will review your previous treatment history and determine whether a different protocol, dosing, or approach at PMC may produce better results for you.
